American Journal of Clinical Dermatology

Papers
(The H4-Index of American Journal of Clinical Dermatology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative290
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE131
The Current State of Systemic Therapy of Metastatic Uveal Melanoma108
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions97
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review81
Prognostic Biomarkers in Evolving Melanoma Immunotherapy80
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review77
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma75
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know74
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments72
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study72
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials70
The Burden of Pediatric Psoriasis: A Systematic Review68
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study66
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review65
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi63
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution61
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology59
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?56
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks55
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion54
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study52
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”52
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation51
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment50
Skin Cancer in Solid Organ Transplant Recipients: A Review50
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry49
48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients49
Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium48
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission47
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management46
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives45
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment44
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis44
Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!44
A Practice Approach to Acne Fulminans in Adolescents44
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis41
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review39
Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances39
0.1757071018219